Published: April 2020
The success of CTLA4, PD-1, and PD-L1 inhibitors paved the way for researchers to explore the vast therapeutic potential of immune checkpoint modulation, enabling the discovery of product candidates against clinical conditions beyond oncology
Roots Analysis has announced the addition of “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030” report to its list of offerings.
Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well.
To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this link
More than 300 immune checkpoint inhibitors and stimulators are currently under development
Nearly 50% of pipeline drugs are being evaluated in the clinical phase and 40% are in preclinical / discovery stage. It is worth mentioning that most of the product candidates are being developed against CD47 immune checkpoint. Further, majority of these therapies (60%) are designed for intravenous administration.
Several big pharma players have next generation immune checkpoint therapy-based initiatives
Over 30 companies engaged in this domain represent large / very large businesses. These companies are developing drugs, either in-house or in partnership with other players, across 25+ immune checkpoint targets for 30+ disease indications.
Partnership activity has grown at an annualized rate of nearly 36%, between 2017 and 2020 (till January)
Maximum number of partnerships were observed in 2019 indicating an increase in the activity in this domain. Majority of these agreements were reported to be research and licensing, representing over 22% of the total number of instances.
Over 450 grants were awarded towards development of these therapies, since 2016
More than 40% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NIAID, and NINDS emerged as key organizations that have offered financial support for time periods exceeding 20 years as well.
In the last 9 years, over 550 clinical trials evaluating next generation immune checkpoint modulators have been registered
The number of clinical trials registered have increased at a CAGR of 37% from 2010 to 2019. Interestingly, nearly 50% of these trials were / are being sponsored by established players. It is worth noting that North America is leading the clinical research efforts in this domain
Presently, the market share is captured by candidates targeting oncological disorders
By 2030, haematological malignancies are likely to represent over 40% of the market share. Further, we believe that, in the foreseen future, the market opportunity is likely to be distributed amongst non-oncological indications such as primary Sjögren's syndrome, lupus nephritis, atopic dermatitis and ulcerative colitis.
To request a sample copy / brochure of this report, please visit this link
The USD 12 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments:
The report features inputs from eminent industry stakeholders, according to whom there is a growing need to evaluate the potency and therapeutic benefits of candidate therapies targeting immune checkpoints beyond PD-1 and PD-L1. The report includes detailed transcripts of the discussions held with industry experts.
The research includes detailed profiles of 30+ drugs being developed by key players (listed below); the profiles also , which also feature an overview of the developer, its financial information (if available), recent developments and an informed future outlook.
For additional details, please visit
or email firstname.lastname@example.org
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry